Condition: Systemic Lupus Erythematosus · Sponsor: GlaxoSmithKline
This is a 2-part study of GSK5926371 in participants with autoimmune rheumatic diseases (ARD). In part 1, participants will receive different doses of GSK5926371 to find a suitable priming dose. In part 2, participants will receive GSK5926371 at doses based on data from part 1. The study is aimed at testing if GSK5926371 is safe, well-tolerated, how the body processes the study drug, how it works in the body, and whether it triggers any immune responses.
This description comes directly from the study's public registry record.
US GSK Clinical Trials Call Center · 877-379-3718 · GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Center · +44 (0) 20 89904466 · GSKClinicalSupportHD@gsk.com
Always discuss trial participation with your own doctor first.
| GSK Investigational Site | Buenos Aires, Argentina | Recruiting |
| GSK Investigational Site | San Miguel de Tucumán, Argentina | Recruiting |
| GSK Investigational Site | Campinas, São Paulo, Brazil | Recruiting |
| GSK Investigational Site | São Paulo, São Paulo, Brazil | Recruiting |
| GSK Investigational Site | Bordeaux, France | Recruiting |
| GSK Investigational Site | Toulouse, France | Recruiting |
| GSK Investigational Site | Cona, Ferrara, Italy | Recruiting |
| GSK Investigational Site | Fukuoka, Japan | Recruiting |
| GSK Investigational Site | Hiroshima, Japan | Recruiting |
| GSK Investigational Site | Hokkaido, Japan | Recruiting |
| GSK Investigational Site | Panama City, Panama | Recruiting |
| GSK Investigational Site | Panama City, Panama | Recruiting |
+ 7 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07371468